122 related articles for article (PubMed ID: 8871002)
1. Long-term survival and symptom palliation in small primary bronchial carcinomas following treatment with intraluminal radiotherapy alone.
Gollins SW; Burt PA; Barber PV; Stout R
Clin Oncol (R Coll Radiol); 1996; 8(4):239-46. PubMed ID: 8871002
[TBL] [Abstract][Full Text] [Related]
2. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients.
Gollins SW; Burt PA; Barber PV; Stout R
Radiother Oncol; 1994 Oct; 33(1):31-40. PubMed ID: 7533304
[TBL] [Abstract][Full Text] [Related]
3. Massive haemoptysis death and other morbidity associated with high dose rate intraluminal radiotherapy for carcinoma of the bronchus.
Gollins SW; Ryder WD; Burt PA; Barber PV; Stout R
Radiother Oncol; 1996 May; 39(2):105-16. PubMed ID: 8735477
[TBL] [Abstract][Full Text] [Related]
4. Treatment of endobronchial metastases with intraluminal radiotherapy.
Quantrill SJ; Burt PA; Barber PV; Stout R
Respir Med; 2000 Apr; 94(4):369-72. PubMed ID: 10845436
[TBL] [Abstract][Full Text] [Related]
5. Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low-dose-rate brachytherapy: second report.
Saito M; Yokoyama A; Kurita Y; Uematsu T; Tsukada H; Yamanoi T
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):673-80. PubMed ID: 10837951
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical benefits of the low dose rate endobronchial irradiation of malignant airway obstructions.
Spásová I; Petera J
Neoplasma; 2001; 48(3):234-40. PubMed ID: 11583295
[TBL] [Abstract][Full Text] [Related]
7. Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
Stranzl H; Gabor S; Mayer R; Prettenhofer U; Wurzinger G; Hackl A
Strahlenther Onkol; 2002 Aug; 178(8):442-5. PubMed ID: 12240550
[TBL] [Abstract][Full Text] [Related]
8. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients.
Ozkok S; Karakoyun-Celik O; Goksel T; Mogulkoc N; Yalman D; Gok G; Bolukbasi Y
Lung Cancer; 2008 Dec; 62(3):326-33. PubMed ID: 18482780
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study.
Sur RK; Levin CV; Donde B; Sharma V; Miszczyk L; Nag S
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):127-33. PubMed ID: 12007950
[TBL] [Abstract][Full Text] [Related]
10. Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor?
Langendijk JA; Tjwa MK; de Jong JM; ten Velde GP; Wouters EF
Radiother Oncol; 1998 Nov; 49(2):175-83. PubMed ID: 10052884
[TBL] [Abstract][Full Text] [Related]
11. [Endoluminal HDR brachytherapy in the palliative treatment of patients with the recurrence of a non-small-cell bronchial carcinoma after prior radiotherapy].
Micke O; Prott FJ; Schäfer U; Wagner W; Pötter R; Willich N
Strahlenther Onkol; 1995 Oct; 171(10):554-9. PubMed ID: 8571174
[TBL] [Abstract][Full Text] [Related]
12. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer.
Chang LF; Horvath J; Peyton W; Ling SS
Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):589-96. PubMed ID: 7509330
[TBL] [Abstract][Full Text] [Related]
13. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study.
Langendijk H; de Jong J; Tjwa M; Muller M; ten Velde G; Aaronson N; Lamers R; Slotman B; Wouters M
Radiother Oncol; 2001 Mar; 58(3):257-68. PubMed ID: 11230886
[TBL] [Abstract][Full Text] [Related]
14. Endobronchial radiotherapy for malignant bronchial obstruction or recurrence.
Hatlevoll R; Karlsen KO; Skovlund E
Acta Oncol; 1999; 38(8):999-1004. PubMed ID: 10665752
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.
Sibley GS; Jamieson TA; Marks LB; Anscher MS; Prosnitz LR
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):149-54. PubMed ID: 9422571
[TBL] [Abstract][Full Text] [Related]
16. Endobronchial brachytherapy for symptom palliation in non-small cell lung cancer--analysis of symptom response, endoscopic improvement and quality of life.
Mallick I; Sharma SC; Behera D
Lung Cancer; 2007 Mar; 55(3):313-8. PubMed ID: 17157949
[TBL] [Abstract][Full Text] [Related]
17. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
Onimaru R; Shirato H; Shimizu S; Kitamura K; Xu B; Fukumoto S; Chang TC; Fujita K; Oita M; Miyasaka K; Nishimura M; Dosaka-Akita H
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):126-35. PubMed ID: 12694831
[TBL] [Abstract][Full Text] [Related]
18. High dose rate endobronchial brachytherapy in the management of primary and recurrent bronchogenic malignancies.
Gustafson G; Vicini F; Freedman L; Johnston E; Edmundson G; Sherman S; Pursel S; Komic M; Chen P; Borrego JC
Cancer; 1995 May; 75(9):2345-50. PubMed ID: 7712446
[TBL] [Abstract][Full Text] [Related]
19. Endoluminal high dose rate brachytherapy in the treatment of primary and recurrent bronchogenic tree malignancies.
Fortunato M; Feijó S; Almeida T; Mendonça V; Aguiar M; Jorge M; Monteiro Grillo I
Rev Port Pneumol; 2009; 15(2):151-64. PubMed ID: 19280066
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
